Researchers are advancing chimeric antigen receptor (CAR) T cell therapies targeting CD70, highly expressed in over 80% of renal cell carcinomas (RCC) but limited in normal tissues. Efforts focus on developing off-the-shelf CAR T products to overcome current challenges including patient-specific manufacturing and modest efficacy. This immunotherapy holds promise to improve outcomes against metastatic RCC, which remains difficult to treat.